PSI-697 is an inhibitor of oral P-selectin (IC50: 125 μM).

PSI-697 inhibits the binding of a soluble human P-selectin to PSGL-1. In vitro, as a reproducible concentration-dependent manner inhibiting 50% of binding at a concentration of 125 μM [1].

PSI-697 (30 mg/kg; p.o.; daily; 6 days) promotes thrombus resolution and reduces inflammation in a baboon model of venous thrombosis. PSI-697 ((30 mg/kg; i.g.; daily) decreases vein wall injury in a rat stenosis model of venous thrombosis. PSI-697 (100 mg/kg; p.o.) reduces thrombus weight by 18% relative to the vehicle, without prolonging bleeding time in a rat venous thrombosis model. PSI-697 (0-50 mg/kg; p.o.) obviously decreases the number of rolling leukocytes by 39% versus vehicle control[1][2].

851546-61-7

C21H18ClNO3

367.83

P-Selectin Inhibitor;PSI-697

DMSO:45.8 mg/mL (124.51 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years